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Background: We have recently developed a novel biocompatible hydrogel, gelatinized copper-capillary alginate gel (GCCAG), with a unique 
microstructure of continuous, parallel channels that can serve as a platform for cell recruitment, tissue formation and drug/cell delivery. The 
innovative feature of GCCAG is its use for intramyocardial injection to modulate scar tissue formation and negative remodeling after myocardial 
infarction (MI).
Methods: Shortly after MI induction in rats, GCCAG was injected (28G needle) into the antero-septal wall in the infarct border zone. Heart function 
was assessed via echo 48h post-MI (baseline) and after 4 weeks (final). Infarcted animals with no injection served as controls.
Results: A significant negative remodeling and wall thinning of the anterior wall occurred in the control group at 4 weeks. In contrast, GCCAG 
injection prevented negative remodeling and wall thinning in the gel group: anterior wall thickening (AWT) and fractional shortening (FS) were 
significantly higher at four weeks (Table 1). The ANOVA results to evaluate if changes in AWT and FS differed as function of time and treatment 
confirm that the differences in LV functional parameters are significant (p = 0.0002 and 0.01 for AWT and FS, respectively). Histology showed gel 
thickened the wall compared to controls and promoted neovascularization within and around the implanted gel.
Conclusions: Intramyocardial GCCAG injection effectively prevents LV negative remodeling and dysfunction after MI in rats.
Parameter GCCAG (n=7) Control (n=6) P Value
AWS, cm
Baseline 0.25±0.08 0.28±0.02 .4
4 wks 0.31±0.06 0.22±0.04 .01
P Value .07 .05
AWD, cm
Baseline 0.22±0.07 0.24±0.02 .64
4 wks 0.20±0.03 0.19±0.04 .72
P Value .38 .04
AWT, %
Baseline 12.4±7.86 16.32±8.12 .4
4wks 52.07±11.22 14.7±12.28 .0002
P Value .0003 .77
FS, %
Baseline 20.7±7.98 24.44±8.02 .42
4 wks 33.78±17.37 22.34±6.66 .058
P Value .007 .59
Table 1.Comparison of LV functional parameters of infarcted rat hearts receiving either Capgel intramyocardial injection or no treatment (Control). 
AWS indicates anterior wall systolic thickness; AWD, anterior wall diastolic thickness; AWT, anterior wall thickening=[(AWS-AWD)/AWS]×100; FS, 
fractional shortening=[(diastolic diameter-systolic diameter)/diastolic diameter]×100
